Our work focused on unraveling other mediators of compensatory resistance to BRAF inhibition, and identified SRC as a pivotal signal transduction node involved in scape mechanisms to BRAF-targeted therapy in preclinical models of BRAFV600E CRC. This evidence concerns the gene SRC and colorectal carcinoma.